Kura Oncology (NASDAQ:KURA) and its newly formed affiliate Caspian Therapeutics outlined plans to develop KO-7246, an oral menin inhibitor, for diabetes, citing preclinical data that the companies ...
Late-stage development, KEYTRUDA combination potential, orphan drug advantages and multiple tumor expansion position IFx-2.0 for faster adoption and portfolio returns.Dublin, Oct. 13, 2026 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results